Australia markets close in 4 hours 22 minutes

Inovio Pharmaceuticals, Inc. (INO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.3600-0.0100 (-0.42%)
At close: 04:00PM EDT
2.3500 -0.01 (-0.42%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.3700
Open2.3900
Bid2.3000 x 36900
Ask2.3600 x 39400
Day's range2.2700 - 2.4750
52-week range1.3800 - 9.9600
Volume6,181,863
Avg. volume7,121,593
Market cap540.537M
Beta (5Y monthly)0.88
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    INOVIO to Report Second Quarter 2022 Financial Results on August 9, 2022

    INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, announced today that second quarter 2022 financial results will be released after the market close on August 9, 2022. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. EDT to discuss financial results and provide a general business update.

  • PR Newswire

    INOVIO Announces Corporate Reorganization to Reduce Operational Expenses and Focus on Opportunities to Bring the Promise of DNA Medicines to Patients

    INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, announced that it has implemented a corporate reorganization designed to extend its cash runway and to focus on key clinical programs with the goal to drive long-term growth.

  • PR Newswire

    INOVIO Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today announced that in connection with the hiring of Dr. Michael John Sumner as Chief Medical Officer, announced on June 27, 2022, the Compensation Committee of INOVIO's Board of Directors approved equity grants to Dr. Sumner as inducement awards under INOVIO's 2022 Inducement Plan (the "In